BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cui D, Cabalu T, Yee KL, Small J, Li X, Liu B, Maciolek C, Smith S, Liu W, McCrea JB, Prueksaritanont T. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. Xenobiotica 2016;46:882-95. [PMID: 26864332 DOI: 10.3109/00498254.2015.1129565] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo S. Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases. Journal of Analytical Toxicology 2018;42:276-83. [DOI: 10.1093/jat/bkx110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
4 Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, Croft M, van Gerven J, Krähenbühl S, Dingemanse J. Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry. CDM 2019;20:254-65. [DOI: 10.2174/1389200220666190206141814] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
5 Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239-247. [PMID: 27471419 DOI: 10.2147/nss.s76910] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
6 Sullinger S, Bryand K, Kerrigan S. Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS). J Anal Toxicol 2017;41:224-9. [PMID: 28035034 DOI: 10.1093/jat/bkw132] [Reference Citation Analysis]
7 Yee KL, Mccrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clin Drug Investig 2018;38:631-8. [DOI: 10.1007/s40261-018-0650-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Boof M, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol 2019;75:195-205. [DOI: 10.1007/s00228-018-2559-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
10 Landolt HP, Holst SC, Valomon A. Clinical and Experimental Human Sleep-Wake Pharmacogenetics. Handb Exp Pharmacol 2019;253:207-41. [PMID: 30443785 DOI: 10.1007/164_2018_175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Landry I, Aluri J, Hall N, Filippov G, Dayal S, Moline M, Reyderman L. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacol Res Perspect 2021;9:e00734. [PMID: 33689224 DOI: 10.1002/prp2.734] [Reference Citation Analysis]
12 Rajana N, Devi DR, Kumar Reddy DN, Babu JM, Basavaiah K, Balakumaran K. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC. J Chromatogr Sci 2020;58:433-44. [PMID: 32134104 DOI: 10.1093/chromsci/bmaa003] [Reference Citation Analysis]
13 Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 2017;86:181-92. [PMID: 28279667 DOI: 10.1016/j.yrtph.2017.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
14 Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. J Pharmacol Exp Ther 2017;362:489-503. [DOI: 10.1124/jpet.117.241596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
15 Skillman B, Kerrigan S. CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Sci Int 2020;312:110307. [PMID: 32473525 DOI: 10.1016/j.forsciint.2020.110307] [Reference Citation Analysis]
16 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
17 Iqbal M, Ezzeldin E, Khalil NY, Alam P, Al-rashood KA. UPLC-MS/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets. Journal of Pharmaceutical and Biomedical Analysis 2019;164:1-8. [DOI: 10.1016/j.jpba.2018.10.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]